D. Keith Grossman Joins ZELTIQ Board of Directors
October 28 2013 - 8:30AM
ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company
focused on developing and commercializing products utilizing its
proprietary controlled-cooling technology platform, today announced
that D. Keith Grossman has joined its Board of Directors.
"We feel very fortunate to welcome Keith to our Board of
Directors. Based on his extensive experience and successful track
record in the medical device industry, we believe that he will be a
valuable resource to the Company, and to me personally, as we
continue to grow and scale our business," said Mark Foley,
President and Chief Executive Officer of ZELTIQ.
"I am delighted to join ZELTIQ, a leading medical technology
company, and an innovator in the non-invasive fat reduction
category with its CoolSculpting® System. I have been following
the Company's impressive growth and success, and I look forward to
working closely with the ZELTIQ board and management team to
further the Company's goals," said D. Keith Grossman.
Mr. Grossman brings over 30 years of experience in the medical
device industry. He most recently served as Chief Executive
Officer, President and a Director of Conceptus, Inc., from December
of 2011 until September of 2013, when the company was acquired by
Bayer Healthcare for over $1.1 billion. Prior to Conceptus,
Mr. Grossman served as a Managing Director of Texas Pacific Group
(TPG) Biotech from 2007 to 2011, where he led the medical device
practice for the venture capital fund, and also served as a Senior
Advisor to the healthcare efforts of the buyout fund, TPG Capital.
Before joining TPG, Mr. Grossman was Chief Executive Officer,
President and a Director of Thoratec Corporation from 1996 to 2006.
During his tenure at Thoratec, revenues grew from $3 million to
over $200 million, while market value grew more than twelve-fold to
over $1.2 billion. Before joining Thoratec, Mr. Grossman's
experience included Sulzermedica and American Hospital Supply
Corporation, in a variety of sales, marketing and general
management positions. Mr. Grossman still serves on the Board
of Directors of Thoratec, as well as the Board of Directors of the
Medical Device Manufacturers Association. He is a past member
of the Boards of Kyphon, Inc. and Intuitive Surgical, Inc., as well
as several private companies.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ is a medical technology company focused on developing and
commercializing products utilizing its proprietary
controlled-cooling technology platform. ZELTIQ's first
commercial product, the CoolSculpting System, is designed to
selectively reduce stubborn fat that may not respond to diet or
exercise. CoolSculpting is based on the scientific principle
that fat cells are more sensitive to cold than the overlying skin
and surrounding tissues. It utilizes patented technology of
precisely controlled cooling to reduce the temperature of fat cells
in the treated area, which is intended to cause fat cell
elimination through a natural biological process known as
apoptosis. ZELTIQ developed CoolSculpting to safely,
noticeably, and measurably reduce the fat layer.
CONTACT: INVESTOR RELATIONS:
Patrick F. Williams
ZELTIQ, SVP and CFO
925-474-2500
Nick Laudico
The Ruth Group for ZELTIQ
646-536-7030
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jul 2023 to Jul 2024